



IFW

Confirmation No.: 7648

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Paul S. Mischel et al.	Examiner:	Not yet assigned
Serial No.:	10/701,490	Group Art Unit:	1642
Filed:	November 5, 2003	Docket:	G&C 30435.148-US-U1
Title:	METHODS AND MATERIALS FOR EXAMINING PATHWAYS ASSOCIATED WITH GLIOBLASTOMA PROGRESSION		

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 5, 2004.

By: 

Name: William J. Wood

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing a Certificate of Mailing under 37 CFR 1.8.
- ☒ Information Disclosure Statement and Form PTO-1449.
- ☒ Cited Reference(s).
- ☒ Return postcard.

Please consider this a **PETITION FOR EXTENSION OF TIME** for a sufficient number of months to enter these papers, if appropriate.

Please charge all fees to Deposit Account No. 50-0494 of Gates & Cooper LLP. A duplicate of this paper is enclosed.

CUSTOMER NUMBER 22462

GATES & COOPER LLP

Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, CA 90045
(310) 641-8797

By: 

Name: William J. Wood

Reg. No.: 42,236

WJW/sjm

(PTO TRANSMITTAL - GENERAL)




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul S. Mischel et al. Examiner: Not yet assigned
Serial No.: 10/701,490 Group Art Unit: 1642
Filed: November 5, 2003 Docket: G&C 30435.148-US-U1
Title: METHODS AND MATERIALS FOR EXAMINING PATHWAYS
ASSOCIATED WITH GLIOBLASTOMA PROGRESSION

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 5, 2004.

By: 
Name: William J. Wood

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each foreign patent document and each non-patent document listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to

establish that the reference(s) are not "prior art". Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please direct any response or inquiry to the below-signed attorney at (310) 641-8797.

Respectfully submitted,

GATES & COOPER LLP
Attorneys for Applicant(s)

Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, California 90045
(310) 641-8797


Date: October 5, 2004

WJW/sjm

By: 

William J. Wood
Reg. No.: 42,236

Form 1449*	Docket Number: G&C 30435.148-US-U1	Application Number: 10/701,490
INFORMATION DISCLOSURE STATEMENT		
Applicant: Paul S. Mischel et al.		
Filing Date: November 5, 2003		Group Art Unit: 1642

							
U.S. PATENT DOCUMENTS							
EXAMINER	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Bianco et al., "Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors," <i>Oncogene</i> , 2003, 22:2812-2822					
		Blume-Jensen et al., "Oncogenic kinase signalling," <i>Nature</i> , May 17, 2001, 411:355-365					
		Burgering et al., "Cell cycle and death control: long live Forkheads," <i>TRENDS in Biochemical Sciences</i> , July 2002, 27(7):352-360					
		Choe et al., "Active Matrix Metalloproteinase 9 Expression Is Associated with Primary Glioblastoma Subtype ¹ ," <i>Clinical Cancer Research</i> , September 2002, 8:2894-2901					
		Daneshmand et al., "A Pharmacodynamic Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Metastatic Colorectal Cancer Patients," <i>Clinical Cancer Research</i> , July 2003, 9:2457-2464					
		Davies et al., "Adenoviral Transgene Expression of MMAC/PTEN in Human Glioma Cells Inhibits Akt Activation and Induces Anoikis ¹ ," <i>Cancer Research</i> , December 1, 1998, 58:5285-5290					
		Davies et al., "Regulation of Akt/PKB Activity, Cellular Growth, and Apoptosis in Prostate Carcinoma Cells by MMAC/PTEN ¹ ," <i>Cancer Research</i> , June 1, 1999, 59:2551-2556					
		Druker et al., "Perspectives on the development of a molecularly targeted agent," <i>Cancer Cell</i> , February 2002, 1:31-36					
		Ekstrand et al., "Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails," <i>Proc. Natl. Acad. Sci. USA</i> , May 1992, 89:4309-4313					
		Ermoian et al., "Dysregulation of PTEN and Protein Kinase B Is Associated with Glioma Histology and Patient Survival ¹ ," <i>Clinical Cancer Research</i> , May 2002, 8:1100-1106					
		Feldkamp et al., "Signal transduction pathways and their relevance in human astrocytomas," <i>Journal of Neuro-Oncology</i> , 1997, 35:223-248					
		Frederick et al., "Diversity and Frequency of Epidermal Growth Factor Receptor Mutations in Human Glioblastomas," March 1, 2000, <i>Cancer Research</i> , 60:1383-1387					
		Gimm et al., "Differential Nuclear and Cytoplasmic Expression of PTEN in Normal Thyroid Tissue, and Benign and Malignant Epithelial Thyroid Tumors," <i>American Journal of Pathology</i> , May 2000, 156(5):1693-1700					
		Gingras et al., "Regulation of translation initiation by FRAP/mTOR," <i>Genes & Development</i> , 2001, 15:807-826					
		Gupta et al., "Local Recurrence in Head and Neck Cancer: Relationship to Radiation Resistance and Signal Transduction," <i>Clinical Cancer Research</i> , March 2002, 8:885-892					

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: G&C 30435.148-US-U1	Application Number: 10/701,490
	Applicant: Paul S. Mischel et al.	
	Filing Date: November 5, 2003	Group Art Unit: 1642

	Hayashi et al., "Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma Multiforme," Brain Pathology, 1997, 7:871-875
	Hidalgo et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy," Oncogene, 2000, 19:6680-6686
	Iijima et al., "c-Raf/MEK/ERK Pathway Controls Protein Kinase C-mediated p70S6K Activation in Adult Cardiac Muscle Cells," The Journal of Biological Chemistry, June 21, 2002, 277(25):23065-23075
	Kilic et al., "Intracranial Inhibition of Platelet-derived Growth Factor-mediated Glioblastoma Cell Growth by an Orally Active Kinase Inhibitor of the 2-Phenylaminopyrimidine Class ¹ ," Cancer Research, September 15, 2000, 60:5143-5150
	Liotta et al., "Clinical Proteomics: Personalized Molecular Medicine," JAMA, November 14, 2001, 286(18):2211-2214
	Liu et al., "PTEN/MMAC1 Mutations and EGFR Amplification in Glioblastomas," Cancer Research, December 1, 1997, 57:5254-5257
	Lorimer et al., "Activation of extracellular-regulated kinases by normal and mutant EGF receptors," Biochimica et Biophysica Acta, 2001, 1538:1-9
	Malik et al., "Immunohistochemical Demonstration of Phospho-Akt in High Gleason Grade Prostate Cancer ¹ ," Clinical Cancer Research, April 2002, 8:1168-1171
	Mischel et al., "Targeted Molecular Therapy of GBM," Brain Pathol, 2003, 13:52-61
	Moscattello et al., "Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor," The Journal of Biological Chemistry, January 2, 1998, 273(1):200-206
	Mutter et al., "Molecular Identification of Latent Precancers in Histologically Normal Endometrium," Cancer Research, June 1, 2001, 61:4311-4314
	Nagane et al., "Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications," Cancer Letters, 2001, 162:S17-S21
	Neshat et al., "Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR," PNAS, August 28, 2001, 98(18):10314-10319
	Nishikawa et al., "A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity," Proc. Natl. Acad. Sci. USA, August 1994, 91:7727-7731
	Perren et al., "Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast," American Journal of Pathology, October 1999, 155(4):1253-1260
	Perren et al., "Mutation and Expression Analyses Reveal Differential Subcellular Compartmentalization of PTEN in Endocrine Pancreatic Tumors Compared to Normal Islet Cells," American Journal of Pathology, October 2000, 157(4):1097-1103
	Sawyers, "Rational therapeutic intervention in cancer: kinases as drug targets," Current Opinion in Genetics & Development, February 2002, 12(1):111-115
	Schmidt et al., "Mutational Profile of the PTEN Gene in Primary Human Astrocytic Tumors and Cultivated Xenografts," Journal of Neuropathology and Experimental Neurology, November 1999, 58(11):1170-1183
	She et al., "Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3'-Kinase/Akt Pathway Signaling," Clinical Cancer Research, October 1, 2003, 9:4340-4346

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: G&C 30435.148-US-U1	Application Number: 10/701,490
	Applicant: Paul S. Mischel et al.	
	Filing Date: November 5, 2003	Group Art Unit: 1642

		Shi et al., "Signal Pathways Involved in Activation of p70 ^{S6K} and Phosphorylation of 4E-BP1 following Exposure of Multiple Myeloma Tumor Cells to Interleukin-6*," The Journal of Biological Chemistry, May 2002, 277(18):15712-15720
		Smith et al., "PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme," Journal of the National Cancer Institute, August 15, 2001, 93(16):1246-1256
		Thomas et al., "Spontaneous Activation and Signaling by Overexpressed Epidermal Growth Factor Receptors in Glioblastoma Cells," Int. J. Cancer, 2003, 104:19-27
		Vivanco et al., "The Phosphatidylinositol 3-Kinase-Akt Pathway in Human Cancer," Nature, July 2002, 2:489-501
		Watanabe et al., "Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas," Brain Pathology, 1996, 6:217-224
		Wikstrand et al., "Cell Surface Localization and Density of the Tumor-associated Variant of the Epidermal Growth Factor Receptor, EGFRvIII ¹ ," Cancer Research, September 15, 1997, 57(18):4130-4140
		Yakes et al., "Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action ¹ ," Cancer Research, July 15, 2002, 62:4132-4141
		Zhou et al., "PTEN Mutational Spectra, Expression Levels, and Subcellular Localization in Microsatellite Stable and Unstable Colorectal Cancers," American Journal of Pathology, August 2002, 161(2):439-447

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	